FUREN Group PharmaceuticalLtd Valuation

Q: What is the Fair Price of 600781 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

600781 (CN¥0.77) is trading below our estimate of [[fair value]] (CN¥9.03)

Is 600781 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600781 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600781 (CN¥0.77) is trading below our estimate of fair value (CN¥9.03)

Significantly Below Fair Value: 600781 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600781?

Key metric: As 600781 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 600781. This is calculated by dividing 600781's market cap by their current revenue.
What is 600781's PS Ratio?
PS Ratio	0.3x
Sales	CN¥1.58b
Market Cap	CN¥482.91m

600781 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.2x
Enterprise Value/EBITDA	-2.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 600781's PS Ratio compare to its peers?

The above table shows the PS ratio for 600781 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7x
603963 Dali Pharmaceuticalco.Ltd	11x	n/a	CN¥698.6m
301075 Tibet Duo Rui Pharmaceutical	5.5x	n/a	CN¥1.7b
300108 Ji Yao Holding Group	4.7x	n/a	CN¥1.9b
600671 Hangzhou TianMuShan Pharmaceutical EnterpriseLtd	6.8x	n/a	CN¥1.1b
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	CN¥482.9m

Price-To-Sales vs Peers: 600781 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (4.3x).

Price to Sales Ratio vs Industry

How does 600781's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	3.7x	12.4%
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	US$66.91m
600664 Harbin Pharmaceutical Group	0.6x	n/a	US$1.34b
000411 Zhejiang Int'l GroupLtd	0.2x	n/a	US$788.21m

6 Companies		Estimated Growth	Market Cap
Industry Avg.	3.7x	19.0%
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	US$66.91m

No more companies

Price-To-Sales vs Industry: 600781 is good value based on its Price-To-Sales Ratio (0.3x) compared to the CN Pharmaceuticals industry average (3.9x).

Price to Sales Ratio vs Fair Ratio

What is 600781's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600781 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 600781's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥50.2b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.49

-2.1%

7.6%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.7b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.25

-1.7%

16.8%